238 related articles for article (PubMed ID: 22454771)
1. Complex Regulation of the Pericellular Proteolytic Microenvironment during Tumor Progression and Wound Repair: Functional Interactions between the Serine Protease and Matrix Metalloproteinase Cascades.
Wilkins-Port CE; Higgins SP; Higgins CE; Kobori-Hotchkiss I; Higgins PJ
Biochem Res Int; 2012; 2012():454368. PubMed ID: 22454771
[TBL] [Abstract][Full Text] [Related]
2. SERPINE1: A Molecular Switch in the Proliferation-Migration Dichotomy in Wound-"Activated" Keratinocytes.
Simone TM; Higgins CE; Czekay RP; Law BK; Higgins SP; Archambeault J; Kutz SM; Higgins PJ
Adv Wound Care (New Rochelle); 2014 Mar; 3(3):281-290. PubMed ID: 24669362
[No Abstract] [Full Text] [Related]
3. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells.
Festuccia C; Angelucci A; Gravina GL; Villanova I; Teti A; Albini A; Bologna M
Int J Cancer; 2000 Feb; 85(3):407-15. PubMed ID: 10652434
[TBL] [Abstract][Full Text] [Related]
4. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
[TBL] [Abstract][Full Text] [Related]
5. Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing.
Wysocki AB; Kusakabe AO; Chang S; Tuan TL
Wound Repair Regen; 1999; 7(3):154-65. PubMed ID: 10417751
[TBL] [Abstract][Full Text] [Related]
6. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
Masson V
Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
[TBL] [Abstract][Full Text] [Related]
7. Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.
Reid JC; Matsika A; Davies CM; He Y; Broomfield A; Bennett NC; Magdolen V; Srinivasan B; Clements JA; Hooper JD
Am J Cancer Res; 2017; 7(11):2257-2274. PubMed ID: 29218249
[TBL] [Abstract][Full Text] [Related]
8. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
9. Effect of lysine antifibrinolytics and cyclooxygenase inhibitors on the proteolytic profile of breast cancer cells interacting with macrophages or endothelial cells.
Afsharimani B; Cabot PJ; Parat MO
Br J Anaesth; 2014 Jul; 113 Suppl 1():i22-31. PubMed ID: 24418973
[TBL] [Abstract][Full Text] [Related]
10. TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1.
Wilkins-Port CE; Ye Q; Mazurkiewicz JE; Higgins PJ
Cancer Res; 2009 May; 69(9):4081-91. PubMed ID: 19383899
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
12. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
[TBL] [Abstract][Full Text] [Related]
13. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
14. PAI-1: An Integrator of Cell Signaling and Migration.
Czekay RP; Wilkins-Port CE; Higgins SP; Freytag J; Overstreet JM; Klein RM; Higgins CE; Samarakoon R; Higgins PJ
Int J Cell Biol; 2011; 2011():562481. PubMed ID: 21837240
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system.
Ellenrieder V; Hendler SF; Ruhland C; Boeck W; Adler G; Gress TM
Int J Cancer; 2001 Jul; 93(2):204-11. PubMed ID: 11410867
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis.
Munshi HG; Wu YI; Mukhopadhyay S; Ottaviano AJ; Sassano A; Koblinski JE; Platanias LC; Stack MS
J Biol Chem; 2004 Sep; 279(37):39042-50. PubMed ID: 15247230
[TBL] [Abstract][Full Text] [Related]
17. Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling.
Mali AV; Joshi AA; Hegde MV; Kadam ShS
Asian Pac J Cancer Prev; 2017 Apr; 18(4):905-915. PubMed ID: 28545187
[TBL] [Abstract][Full Text] [Related]
18. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Holst-Hansen C; Low JA; Stephens RW; Johnson MD; Carmeliet P; Frandsen TL; Brünner N; Dickson RB
Breast Cancer Res Treat; 2001 Aug; 68(3):225-37. PubMed ID: 11727959
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
20. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
Nalbandian A; Djakiew D
Clin Exp Metastasis; 2006; 23(2):107-16. PubMed ID: 16912916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
